Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis
Top Cited Papers
Open Access
- 7 July 2015
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 132 (1), 27-39
- https://doi.org/10.1161/circulationaha.114.013876
Abstract
Background—Patients with kidney disease have disordered bone and mineral metabolism, including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These elevated concentrations are associated with cardiovascular and all-cause mortality. The objective was to determine the effects of the calcimimetic cinacalcet (versus placebo) on reducing serum FGF23 and whether changes in FGF23 are associated with death and cardiovascular events. Methods and Results—This was a secondary analysis of a randomized clinical trial comparing cinacalcet to placebo in addition to conventional therapy (phosphate binders/vitamin D) in patients receiving hemodialysis with secondary hyperparathyroidism (intact parathyroid hormone ≥300 pg/mL). The primary study end point was time to death or a first nonfatal cardiovascular event (myocardial infarction, hospitalization for angina, heart failure, or a peripheral vascular event). This analysis included 2985 patients (77% of randomized) with serum samples at baseline and...Keywords
This publication has 33 references indexed in Scilit:
- Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled studyBMC Nephrology, 2013
- Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing DialysisNew England Journal of Medicine, 2012
- Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysisBone, 2012
- Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidismNephrology Dialysis Transplantation, 2011
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney diseaseKidney International, 2011
- FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatmentNephrology Dialysis Transplantation, 2010
- High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patientsNephrology Dialysis Transplantation, 2009
- Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the communityAtherosclerosis, 2009
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008